<DOC>
	<DOCNO>NCT01299636</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose recommend dose evaluate safety tolerability PM060184 .</brief_summary>
	<brief_title>Study PM060184 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This trial intend determine maximum tolerate dose recommend dose , evaluate safety tolerability , determine pharmacokinetics evaluate antitumor activity PM060184 patient advance solid tumor .</detailed_description>
	<criteria>Inclusion criterion 1 . Voluntary sign dated write informed consent . 2 . Patients advance solid tumor refractory Standard therapy . 3 . Age &gt; /= 18 year . 4 . Recovery drugrelated adverse event ( AEs ) previous treatment , exclude alopecia . 5 . Normal laboratory value within seven day prior treatment administration . 6 . Women childbearing potential must negative serum pregnancy test study entry . Both men woman must agree use medically acceptable method contraception throughout treatment period three month discontinuation treatment . Exclusion criteria 1 . Pregnant lactating woman . 2 . Less three week radiation therapy last dose hormonal therapy , biological therapy chemotherapy 3 . Prior treatment investigational product le 30 day prior first . 4 . Central Nervous System metastases 5 . Other relevant disease adverse clinical condition : Increased cardiac risk : Presence significant neurological psychiatric disorder Neuropathy Active infection require treatment . Liver disease ( e.g. , cirrhosis , hepatitis ) . Immunocompromised patient . Any major illness . 6 . Limitation patient 's ability comply treatment . 7 . Known hypersensitivity component drug product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>PM060184</keyword>
	<keyword>Phase I</keyword>
	<keyword>Pharma Mar</keyword>
</DOC>